Biomerieux SA (BIM) - Total Liabilities

Latest as of December 2025: €1.47 Billion EUR ≈ $1.72 Billion USD

Based on the latest financial reports, Biomerieux SA (BIM) has total liabilities worth €1.47 Billion EUR (≈ $1.72 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Biomerieux SA - Total Liabilities Trend (2005–2025)

This chart illustrates how Biomerieux SA's total liabilities have evolved over time, based on quarterly financial data. See Biomerieux SA (BIM) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Biomerieux SA Competitors by Total Liabilities

The table below lists competitors of Biomerieux SA ranked by their total liabilities.

Company Country Total Liabilities
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
Germany €288.99 Billion
Orion Oyj B
HE:ORNBV
Finland €726.20 Million
Primerica Inc
NYSE:PRI
USA $12.16 Billion
UNICHARM CORP. SP.ADR 1
F:UN41
Germany €331.92 Billion
Alpha Services and Holdings S.A.
AT:ALPHA
Greece €64.85 Billion
Chang Hwa Commercial Bank Ltd
TW:2801
Taiwan NT$3.26 Trillion
Tongwei Co Ltd
SHG:600438
China CN¥138.81 Billion

Liability Composition Analysis (2005–2025)

This chart breaks down Biomerieux SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIM market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.39 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.29 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.26 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biomerieux SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biomerieux SA (2005–2025)

The table below shows the annual total liabilities of Biomerieux SA from 2005 to 2025.

Year Total Liabilities Change
2025-12-31 €1.47 Billion
≈ $1.72 Billion
-5.79%
2024-12-31 €1.56 Billion
≈ $1.82 Billion
+3.45%
2023-12-31 €1.51 Billion
≈ $1.76 Billion
-2.38%
2022-12-31 €1.54 Billion
≈ $1.80 Billion
+7.10%
2021-12-31 €1.44 Billion
≈ $1.69 Billion
-0.35%
2020-12-31 €1.45 Billion
≈ $1.69 Billion
-5.29%
2019-12-31 €1.53 Billion
≈ $1.79 Billion
+1.66%
2018-12-31 €1.50 Billion
≈ $1.76 Billion
+19.88%
2017-12-31 €1.25 Billion
≈ $1.47 Billion
-10.96%
2016-12-31 €1.41 Billion
≈ $1.65 Billion
+10.74%
2015-12-31 €1.27 Billion
≈ $1.49 Billion
+6.65%
2014-12-31 €1.19 Billion
≈ $1.39 Billion
+28.25%
2013-12-31 €929.30 Million
≈ $1.09 Billion
+46.81%
2012-12-31 €633.00 Million
≈ $740.04 Million
-3.92%
2011-12-31 €658.80 Million
≈ $770.21 Million
+39.40%
2010-12-31 €472.60 Million
≈ $552.52 Million
+4.26%
2009-12-31 €453.30 Million
≈ $529.96 Million
-9.48%
2008-12-31 €500.80 Million
≈ $585.49 Million
+26.11%
2007-12-31 €397.10 Million
≈ $464.25 Million
+3.93%
2006-12-31 €382.10 Million
≈ $446.72 Million
-6.26%
2005-12-31 €407.60 Million
≈ $476.53 Million
--

About Biomerieux SA

PA:BIM France Diagnostics & Research
Market Cap
$9.32 Billion
€7.97 Billion EUR
Market Cap Rank
#2555 Global
#51 in France
Share Price
€67.55
Change (1 day)
-0.30%
52-Week Range
€67.45 - €128.30
All Time High
€138.61
About

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more